{
    "organizations": [],
    "uuid": "7991ac236db010f8afda18ccdce677c0c0c06708",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dynavax-provides-new-durability-of/brief-dynavax-provides-new-durability-of-response-data-for-sd-101-in-combination-with-keytruda-in-melanoma-idUSFWN1RU13L",
    "ord_in_thread": 0,
    "title": "BRIEF-Dynavax Provides New Durability Of Response Data For SD-101 In Combination With Keytruda In Melanoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17 (Reuters) - Dynavax Technologies Corp:\n* DYNAVAX PROVIDES NEW DURABILITY OF RESPONSE DATA FOR SD-101 IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) IN MELANOMA AT THE 2018 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING\n* DYNAVAX TECHNOLOGIES CORP - COMBINATION THERAPY WAS WELL TOLERATED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-17T21:18:00.000+03:00",
    "crawled": "2018-04-18T18:02:31.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "dynavax",
        "technology",
        "corp",
        "dynavax",
        "provides",
        "new",
        "durability",
        "response",
        "data",
        "combination",
        "keytruda",
        "pembrolizumab",
        "melanoma",
        "american",
        "association",
        "cancer",
        "research",
        "annual",
        "meeting",
        "dynavax",
        "technology",
        "corp",
        "combination",
        "therapy",
        "well",
        "tolerated",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}